Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials

Advanced Drug Delivery Reviews

Volumn 106, Issue , 2016, Pages 223-241

  Aguirre, T A S ^a   Teijeiro Osorio, D ^b   Rosa, M ^c   Coulter, I S ^c   Alonso, M J ^b   Brayden, D J ^d  

^a UNIVERSITY OF CAXIAS DO SUL   (Brazil)

^b University of Santiago de Compostela ^*  (Spain)

^c DUBLIN CITY UNIVERSITY   (Ireland)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Intestinal permeation enhancers; Oral nanotechnology; Oral peptides; Peptide clinical trials; Therapeutic peptides

Indexed keywords

BIOCHEMISTRY; DRUG PRODUCTS; ENZYME INHIBITION; NANOTECHNOLOGY;

CLINICAL TRIAL; ENTERIC-COATED TABLETS; INTESTINAL PERMEATIONS; ORAL BIOAVAILABILITIES; PENETRATION ENHANCERS; PHARMACEUTICAL INDUSTRY; PRECLINICAL DEVELOPMENT; THERAPEUTIC PEPTIDES;

PEPTIDES;

CERTOLIZUMAB PEGOL; COLISTIN; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CYCLOSPORIN A; DESMOPRESSIN; DIFELIKEFALIN; DOLCANATIDE; EXCIPIENT; EXENDIN 4; GLUTATHIONE; INSULIN; LINACLOTIDE; MACROGOL; NANOPARTICLE; OCTREOTIDE; PARATHYROID HORMONE; PEGVISOMANT; PEPTIDASE; PEPTIDE; PLACEBO; PLECANATIDE; PRAMLINTIDE; SALCATONIN; SEMAGLUTIDE; SUROTOMYCIN; TALTIRELIN; TYROTHRICIN; UNINDEXED DRUG; VANCOMYCIN; VOCLOSPORIN;

ACROMEGALY; AREA UNDER THE CURVE; CACHEXIA; CHRONIC CONSTIPATION; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; CYSTIC FIBROSIS; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; HIP OSTEOARTHRITIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; IRRITABLE COLON; KNEE OSTEOARTHRITIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MICRONEEDLE; MOUTH PAIN; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOARTHRITIS; OSTEOPOROSIS; PHARYNGITIS; PILL; PRIORITY JOURNAL; REVIEW; SPINOCEREBELLAR DEGENERATION; TIME TO MAXIMUM PLASMA CONCENTRATION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VOMITING; ANIMAL; BIOAVAILABILITY; CLINICAL TRIAL (TOPIC); INTESTINE ABSORPTION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; EXCIPIENTS; HUMANS; INTESTINAL ABSORPTION; PEPTIDES;

EID: 84960156330     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.02.004     Document Type: Review

References (195)

1. [1] Lopes, M., Simões, S., Veiga, F., Seiça, R., Ribeiro, A., Why most oral insulin formulations do not reach clinical trials. Ther. Deliv. 6 (2015), 973–987, 10.4155/TDE.15.47.
2. [2] Fosgerau, K., Hoffmann, T., Peptide therapeutics: current status and future directions. Drug Discov. Today 20 (2015), 122–128, 10.1016/j.drudis.2014.10.003.
3. [3] Choonara, B.F., Choonara, Y.E., Kumar, P., Bijukumar, D., du Toit, L.C., Pillay, V., A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol. Adv. 32 (2014), 1269–1282, 10.1016/j.biotechadv.2014.07.006.
4. [4] Hassani, L.N., Lewis, A., Richard, J., Oral peptide delivery—technology landscape and current status. OnDrugDelivery. 59 (2015), 12–17.
5. [5] Amylin, E.L., Challenges in the large scale production of peptides. Spec. Chem. Mag., 26–28, 2013.
6. [6] Uhlig, T., Kyprianou, T., Martinelli, F.G., Oppici, C.A., Heiligers, D., Hills, D., et al. The emergence of peptides in the pharmaceutical business: from exploration to exploitation. EuPA Open Proteomics. 4 (2014), 58–69, 10.1016/j.euprot.2014.05.003.
7. [7] Lewis, A.L., Richard, J., Challenges in the delivery of peptide drugs: an industry perspective. Ther. Deliv. 6 (2015), 149–163, 10.4155/tde.14.111.
8. [8] Jenkins, K. II, Needle phobia: a psychological perspective. Br. J. Anaesth. 113 (2014), 4–6, 10.1093/bja/aeu013.
9. [9] Melmed, S., Popovic, V., Bidlingmaier, M., Mercado, M., van der Lely, A.J., Biermasz, N., et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter Phase III trial. J. Clin. Endocrinol. Metab. 100 (2015), 1699–1708, 10.1210/jc.2014-4113.
10. [10] Hanefeld, M., Monnier, L., Schnell, O., Owens, D., Early treatment with basal insulin glargine in people with type 2 diabetes: lessons from ORIGIN and other cardiovascular trials. Diabetes Ther., Feb. 10 2016 ([Epub ahead of print]. PMID: 26861811).
11. [11] Binkley, N., Bolognese, M., Sidorowicz-Bialynicka, A., Vally, T., Trout, R., Miller, C., et al. A Phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the oral calcitonin in postmenopausal osteoporosis (ORACAL) trial. J. Bone Miner. Res. 27 (2012), 1821–1829, 10.1002/jbmr.1602.
12. [12] EMA, European Medicines Agency recommends limiting long-term use of calcitonin medicines, Eur. Med. Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/07/news_detail_001573.jsp&mid=WC0b01ac058004d5c1, 2012 (accessed December 15, 2015).
13. [13] Perrone, M., Calcitonin salmon osteoporosis: FDA panel votes against use of drug because of cancer risks. http://www.huffingtonpost.com/2013/03/06/calcitonin-salmon-osteoporosis-drug-cancer-risk-fda_n_2819479.html, 2013 (accessed December 15, 2015).
14. [14] Wells, G., Chernoff, J., Gilligan, J.P., Krause, D.S., Does salmon calcitonin cause cancer? A review and meta-analysis. Osteoporos. Int., 1-7, 2015, 10.1007/s00198-015-3339-z.
15. [15] Binkley, N., Bone, H., Gilligan, J.P., Krause, D.S., Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial. Osteoporos. Int. 25 (2014), 2649–2656, 10.1007/s00198-014-2796-0.
16. [16] Maher, S., Ryan, B., Duffy, A., Brayden, D.J., Formulation strategies to improve oral peptide delivery. Pharm. Pat. Anal. 3 (2014), 313–336, 10.4155/ppa.14.15.
17. [17] Novartis, Sandimmune® soft gelatin capsules—product label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/050625s030lbl.pdf, 2003 (accessed January 13, 2016).
18. [18] Dunn, C.J., Wagstaff, A.J., Perry, C.M., Plosker, G.L., Goa, K.L., Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Drugs 61 (2001), 1957–2016.
19. [19] Larsen, A., Holm, R., Pedersen, M.L., Müllertz, A., Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis. Pharm. Res. 25 (2008), 2769–2777, 10.1007/s11095-008-9641-0.
20. [20] Ritschel, W.A., Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral. Clin. Transpl. 10 (1996), 364–373.
21. [21] Novartis, NEORAL® - Product Label, http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050715s035,050716s038lbl.pdf, 2015 (accessed January 13, 2016).
22. [22] Hauss, D.J., Oral lipid-based formulations. Adv. Drug Deliv. Rev. 59 (2007), 667–676, 10.1016/j.addr.2007.05.006.
23. [23] Kovarik, J.M., Mueller, E.A., van Bree, J.B., Tetzloff, W., Kutz, K., Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J. Pharm. Sci. 83 (1994), 444–446.
24. [24] Mueller, E.A., Kovarik, J.M., van Bree, J.B., Tetzloff, W., Grevel, J., Kutz, K., Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm. Res. 11 (1994), 301–304, 10.1023/A:1018923912135.
25. [25] Mueller, E.A., Kovarik, J.M., van Bree, J.B., Grevel, J., Lücker, P.W., Kutz, K., Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm. Res. 11 (1994), 151–1555.
26. [26] Van Mourik, I.D.M., Thomson, M., Kelly, D.A., Comparison of pharmacokinetics of neoral and sandimmune in stable pediatric liver transplant recipients. Liver Transplant. Surg. 5 (1999), 107–111, 10.1002/lt.500050203.
27. [27] Zaoral, M., Kolc, J., Šorm, F., Amino acids and peptides. LXXI. Synthesis of 1-deamino-8-D-γ-aminobutyrine-vasopressin, 1-deamino-8-D-lysine-vasopressin, and 1-deamino-8-D-arginine-vasopressin, Collect. Czechoslov. Chem. Commun. 32 (1967), 1250–1257, 10.1135/cccc19671250.
28. [28] Zaoral, M., DDAVP (Desmopressin) and solid phase peptide synthesis. Biopolymers, 90, 2008, 213, 10.1002/bip.20936.
29. [29] Pharmaceuticals, F., Minirin® Tablets - New Zealand data sheet. 2010 http://www.medsafe.govt.nz/profs/datasheet/m/Minirintab.pdf (accessed December 15, 2015).
30. [30] Sanofi-Aventis, DDAVP® Melt - Product Label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017922s038,018938s027,019955s013lbl.pdf, 2007 (accessed January 13, 2016).
31. [31] Weinberg, R.S., Grecco, M.O., Ferro, G.S., Seigelshifer, D.J., Perroni, N.V., Terrier, F.J., et al. A Phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients. Springerplus, 4, 2015, 428, 10.1186/s40064-015-1217-y.
32. [32] Mannucci, P.M., Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 90 (1997), 2515–2521.
33. [33] Fukuchi, I., Asahi, T., Kawashima, K., Kawashima, Y., Yamamura, M., Matsuoka, Y., et al. Effects of taltirelin hydrate (TA-0910), a novel thyrotropin-releasing hormone analog, on in vivo dopamine release and turnover in rat brain. Arzneimittelforschung 48 (1998), 353–359.
34. [34] Thirunarayanan, N., Nir, E.A., Raaka, B.M., Gershengorn, M.C., Thyrotropin-releasing hormone receptor type 1 (TRH-R1), not TRH-R2, primarily mediates taltirelin actions in the CNS of mice. Neuropsychopharmacology 38 (2013), 950–956, 10.1038/npp.2012.256.
35. [35] Launch of Ceredist OD Tablets 5, Press Release, Mitsubishi Tanabe Pharma Corporation. http://www.mt-pharma.co.jp/e/release/nr/2009/pdf/e091022.pdf, 2009 (accessed December 15, 2015).
36. [36] Urayama, A., Yamada, S., Kimura, R., Zhang, J., Watanabe, Y., Neuroprotective effect and brain receptor binding of taltirelin, a novel thyrotropin-releasing hormone (TRH) analogue, in transient forebrain ischemia of C57BL/6J mice. Life Sci. 72 (2002), 601–607, 10.1016/S0024-3205(02)02268-3.
37. [37] 0384 Effects of taltirelin hydrate for cerebellar ataxias. J. Neurol. Sci., 238, 2005, S197, 10.1016/S0022-510X(05)80752-X.
38. [38] Kelly, J.A., Boyle, N.T., Cole, N., Slator, G.R., Colivicchi, M.A., Stefanini, C., et al. First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models. Neuropharmacology 89C (2014), 193–203, 10.1016/j.neuropharm.2014.09.024.
39. [39] Re: Re-submission of GRAS notice for glutathione (original GRN 000244). http://www.fda.gov/downloads/food/ingredientspackaginglabeling/gras/noticeinventory/ucm269318, 2009 (accessed December 15, 2015).
40. [40] Reduced L-glutathione—FDA orphan drug designation. http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=077493, 1994 (accessed December 15, 2015).
41. [41] EMA, Public summary of opinion on orphan designation. http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500006272.pdf, 2014 (accessed December 15, 2015).
42. [42] FDA, Drugs@FDA. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/, 2015 (accessed December 15, 2015).
43. [43] Gupta, S.C., Patchva, S., Aggarwal, B.B., Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 15 (2013), 195–218, 10.1208/s12248-012-9432-8.
44. [44] Awasthi, S., Pandya, U., Singhal, S.S., Lin, J.T., Thiviyanathan, V., Seifert, W.E., et al. Curcumin–glutathione interactions and the role of human glutathione S-transferase P1-1. Chem. Biol. Interact. 128 (2000), 19–38, 10.1016/S0009-2797(00)00185-X.
45. [45] Visca, A., Bishop, C.T., Hilton, S., Hudson, V.M., Oral reduced L-glutathione improves growth in pediatric cystic fibrosis patients. J. Pediatr. Gastroenterol. Nutr. 60 (2015), 802–810, 10.1097/MPG.0000000000000738.
46. [46] Visca, A., Bishop, C.T., Hilton, S.C., Hudson, V.M., Improvement in clinical markers in CF patients using a reduced glutathione regimen: an uncontrolled, observational study. J. Cyst. Fibros. 7 (2008), 433–436, 10.1016/j.jcf.2008.03.006.
47. [47] L-Glutathione, Reduced, Investigator's Brochure. 2007 http://uvicf.org/researchnewsite/glutathionenewsite/IBMay2007.pdf (accessed December 7, 2015).
48. [48] Iqbal, J., Sarti, F., Perera, G., Bernkop-Schnürch, A., Development and in vivo evaluation of an oral drug delivery system for paclitaxel. Biomaterials 32 (2011), 170–175, 10.1016/j.biomaterials.2010.09.036.
49. [49] Busby, R.W., Bryant, A.P., Bartolini, W.P., Cordero, E.A., Hannig, G., Kessler, M.M., et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur. J. Pharmacol. 649 (2010), 328–335, 10.1016/j.ejphar.2010.09.019.
50. [50] Fretzen, A., Witowski, S., Grossi, A., Zhao, H., Dedhiya, M., Mo, Y., Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration., US 8802628 B2. 2014.
51. [51] Chey, W.D., Lembo, A.J., Lavins, B.J., Shiff, S.J., Kurtz, C.B., Currie, M.G., et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am. J. Gastroenterol. 107 (2012), 1702–1712, 10.1038/ajg.2012.254.
52. [52] Kang, S.B., Marchelletta, R.R., Penrose, H., Docherty, M.J., McCole, D.F., A comparison of linaclotide and lubiprostone dosing regimens on ion transport responses in human colonic mucosa. Pharmacol. Res. Perspect. 3 (2015), 1–12, 10.1002/prp2.128.
53. [53] LINZESS, product label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202811s004lbl.pdf, 2012 (accessed December 15, 2015).
54. [54] Pharma, Ironwood, https://www.ironwoodpharma.com/research-and-development, 2015 (accessed December 15, 2015).
55. [55] Vesga, O., Agudelo, M., Salazar, B.E., Rodriguez, C.A., Zuluaga, A.F., Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob. Agents Chemother. 54 (2010), 3271–3279, 10.1128/AAC.01044-09.
56. [56] Deresinski, S., Vancomycin: does it still have a role as an antistaphylococcal agent?. Expert Rev. Anti-Infect. Ther. 5 (2007), 393–401, 10.1586/14787210.5.3.393.
57. [57] Vancocin capsules, product label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050606s028lbl.pdf, 2011 (accessed December 15, 2015).
58. [58] Anderson, K.E., Eliot, L.A., Stevenson, B.R., Rogers, J.A., Formulation and evaluation of a folic acid receptor-targeted oral vancomycin liposomal dosage form. Pharm. Res. 18 (2001), 316–322, 10.1023/A:1011002913601.
59. [59] Li, J., Milne, R.W., Nation, R.L., Turnidge, J.D., Coulthard, K., Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob. Agents Chemother. 47 (2003), 1364–1370, 10.1128/AAC.47.4.1364-1370.2003.
60. [60] K. Koyama, Y., Kurosasa, A., Tsuchiya, A., Takakuta, A new antibiotic “colistin” produced by spore-forming soil bacteria. J. Antibiot. 3 (1950), 457–458.
61. [61] Biswas, S., Brunel, J.-M., Dubus, J.-C., Reynaud-Gaubert, M., Rolain, J.-M., Colistin: an update on the antibiotic of the 21st century. Expert Rev. Anti-Infect. Ther. 10 (2012), 917–934, 10.1586/eri.12.78.
62. [62] Catry, B., Cavaleri, M., Baptiste, K., Grave, K., Grein, K., Holm, A., et al. Use of colistin-containing products within the European Union and European Economic Area (EU/EEA): development of resistance in animals and possible impact on human and animal health. Int. J. Antimicrob. Agents 46 (2015), 297–306, 10.1016/j.ijantimicag.2015.06.005.
63. [63] Houben, A.J.M., Oostdijk, E.A.N., van der Voort, P.H.J., Monen, J.C.M., Bonten, M.J.M., van der Bij, A.K., Selective decontamination of the oropharynx and the digestive tract, and antimicrobial resistance: a 4 year ecological study in 38 intensive care units in the Netherlands. J. Antimicrob. Chemother. 69 (2014), 797–804, 10.1093/jac/dkt416.
64. [64] Halaby, T., Al Naiemi, N., Kluytmans, J., van der Palen, J., Vandenbroucke-Grauls, C.M.J.E., Emergence of colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit. Antimicrob. Agents Chemother. 57 (2013), 3224–3229, 10.1128/AAC.02634-12.
65. [65] EMA, European Medicines Agency Completes Review of Polymyxin-Based Medicines. 2014, 1–4 (http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Polymyxin_31/WC500176333.pdf accessed December 15, 2015).
66. [66] Dubos, R.J., Studies on a bactericidal agent extracted from a soil bacillus: I. Preparation of the agent. Its activity in vitro. J. Exp. Med. 70 (1939), 1–10.
67. [67] Stauss-Grabo, M., Atiye, S., Le, T., Kretschmar, M., Decade-long use of the antimicrobial peptide combination tyrothricin does not pose a major risk of acquired resistance with gram-positive bacteria and Candida spp. Pharmazie 69 (2014), 838–841.
68. [68] Peter Davey, G.T., Wilcox, Mark H., Irving, Will, Mechanisms of action and resistance to modern antibacterials, with a history of their development. Antimicrobial Chemotherapy, seventh ed., 2015, Oxford University Press, Oxford.
69. [69] Yudin, A.K., Macrocycles: lessons from the distant past, recent developments, and future directions. Chem. Sci. 6 (2015), 30–49, 10.1039/C4SC03089C.
70. [70] White, C.J., Yudin, A.K., Contemporary strategies for peptide macrocyclization. Nat. Chem. 3 (2011), 509–524, 10.1038/nchem.1062.
71. [71] Cain, B.C., Excited about cycling, BioCentury. Bernstein Rep. Biobus. 20 (2013), 9–14.
72. [72] Busque, S., Cantarovich, M., Mulgaonkar, S., Gaston, R., Gaber, A.O., Mayo, P.R., et al. The PROMISE study: aphase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am. J. Transplant. 11 (2011), 2675–2684, 10.1111/j.1600-6143.2011.03763.x.
73. [73] Kotz, J., Macrocyclic peptide dash. Sci. Exch., 5, 2012, 15.
74. [74] Immunopharma: severe pain relief (IPP-102199). http://www.immupharma.org/pain-relief-treatments, 2015 (accessed December 15, 2015).
75. [75] Lewis, R.J., Garcia, M.L., Therapeutic potential of venom peptides. Nat. Rev. Drug Discov. 2 (2003), 790–802, 10.1038/nrd1197.
76. [76] King, G., Venoms to drugs : translating venom peptides into therapeutics. Aust. Biochem. 44 (2013), 13–16.
77. [77] Reid, P.F., Alpha-cobratoxin as a possible therapy for multiple sclerosis: a review of the literature leading to its development for this application. Crit. Rev. Immunol. 27 (2007), 291–302, 10.1615/CritRevImmunol.v27.i4.10.
78. [78] ReceptoPharm's research and development pipeline. http://www.receptopharm.com/drug_development/pipeline.php, 2015 (accessed December 15, 2015).
79. [79] CR845: CARA possesses peripherally-selective molecules that interact with kappa opioid receptors present on peripheral, pain-sensing nerves. http://www.caratherapeutics.com/cr845.shtml, 2015 (accessed December 15, 2015).
80. [80] Fox, J.L., Antimicrobial peptides stage a comeback. Nat. Biotechnol. 31 (2013), 379–382, 10.1038/nbt.2572.
81. [81] Cézard, C., Silva-pires, V., Mullié, C., Sonnet, P., Antibacterial Peptides : A Review. 926–937, 2011, FORMATEX.
82. [82] Wang, Z., APD: the Antimicrobial Peptide Database. Nucleic Acids Res. 32 (2004), 590D–5592, 10.1093/nar/gkh025.
83. [83] Alam, M.Z., Wu, X., Mascio, C., Chesnel, L., Hurdle, J.G., Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile. Antimicrob. Agents Chemother. 59 (2015), 5165–5170, 10.1128/AAC.01087-15.
84. [84] Karsdal, M.A., Riis, B.J., Mehta, N., Stern, W., Arbit, E., Christiansen, C., et al. Lessons learned from the clinical development of oral peptides. Br. J. Clin. Pharmacol. 79 (2015), 720–732, 10.1111/bcp.12557.
85. [85] Aungst, B.J., Absorption enhancers: applications and advances. AAPS J. 14 (2012), 10–18, 10.1208/s12248-011-9307-4.
86. [86] Aungst, B.J., Intestinal permeation enhancers. J. Pharm. Sci. 89 (2000), 429–442, 10.1002/(SICI)1520-6017 ((200004)89:4 < 429::AID-JPS1 > 3.0.CO;2-J).
87. [87] Maher, S., Kennelly, R., Bzik, V.A., Baird, A.W., Wang, X., Winter, D., et al. Evaluation of intestinal absorption enhancement and local mucosal toxicity of two promoters. I. Studies in isolated rat and human colonic mucosae. Eur. J. Pharm. Sci. 38 (2009), 291–300, 10.1016/j.ejps.2009.09.001.
88. [88] Petersen, S.B., Nolan, G., Maher, S., Rahbek, U.L., Guldbrandt, M., Brayden, D.J., Evaluation of alkylmaltosides as intestinal permeation enhancers: comparison between rat intestinal mucosal sheets and Caco-2 monolayers. Eur. J. Pharm. Sci. 47 (2012), 701–712, 10.1016/j.ejps.2012.08.010.
89. [89] Maher, S., Wang, X., Bzik, V., McClean, S., Brayden, D.J., Evaluation of intestinal absorption and mucosal toxicity using two promoters. II. Rat instillation and perfusion studies. Eur. J. Pharm. Sci. 38 (2009), 301–311, 10.1016/j.ejps.2009.07.011.
90. [90] Woodley, J.F., Enzymatic barriers for GI peptide and protein delivery. Crit. Rev. Ther. Drug Carrier Syst. 11 (1994), 61–95.
91. [91] Wang, J., Yadav, V., Smart, A.L., Tajiri, S., Basit, A.W., Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 Peptide drugs. Mol. Pharm. 12 (2015), 966–973, 10.1021/mp500809f.
92. [92] Welling, S.H., Hubálek, F., Jacobsen, J., Brayden, D.J., Rahbek, U.L., Buckley, S.T., The role of citric acid in oral peptide and protein formulations: relationship between calcium chelation and proteolysis inhibition. Eur. J. Pharm. Biopharm. 86 (2014), 544–551, 10.1016/j.ejpb.2013.12.017.
93. [93] Youn, Y.S., Jung, J.Y., Oh, S.H., Yoo, S.D., Lee, K.C., Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. J. Control. Release 114 (2006), 334–342, 10.1016/j.jconrel.2006.06.007.
94. [94] Ryan, S.M., Wang, X., Mantovani, G., Sayers, C.T., Haddleton, D.M., Brayden, D.J., Conjugation of salmon calcitonin to a combed-shaped end functionalized poly(poly(ethylene glycol) methyl ether methacrylate) yields a bioactive stable conjugate. J. Control. Release 135 (2009), 51–59, 10.1016/j.jconrel.2008.12.014.
95. [95] Wang, J., Chow, D., Heiati, H., Shen, W., Reversible lipidization for the oral delivery of salmon calcitonin. J. Control. Release 88 (2003), 369–380.
96. [96] Cheng, W., Lim, L., Synthesis, characterization and in vivo activity of salmon calcitonin coconjugated with lipid and polyethylene glycol. J. Pharm. Sci. 98 (2009), 1438–1451, 10.1002/jps.21524.
97. [97] Cheng, W., Satyanarayanajois, S., Lim, L.-Y., Aqueous-soluble, non-reversible lipid conjugate of salmon calcitonin: synthesis, characterization and in vivo activity. Pharm. Res. 24 (2007), 99–110, 10.1007/s11095-006-9128-9.
98. [98] Cheng, W., Lim, L.-Y., Lipeo-sCT: a novel reversible lipidized salmon calcitonin derivative, its biophysical properties and hypocalcemic activity. Eur. J. Pharm. Sci. 37 (2009), 151–159, 10.1016/j.ejps.2009.02.004.
99. [99] Rubinstein, A., Tirosh, B., Baluom, M., Nassar, T., David, A., Radai, R., et al. The rationale for peptide drug delivery to the colon and the potential of polymeric carriers as effective tools., 46, 1997, 59–73.
100. [100] Gibson, S.A., McFarlan, C., Hay, S., MacFarlane, G.T., Significance of microflora in proteolysis in the colon. Appl. Environ. Microbiol. 55 (1989), 679–683.
101. [101] Rubinstein, A., Colonic drug delivery. Drug Discov. Today Technol. 2 (2005), 33–37, 10.1016/j.ddtec.2005.05.021.
102. [102] Maroni, A., Zema, L., Del Curto, M.D., Foppoli, A., Gazzaniga, A., Oral colon delivery of insulin with the aid of functional adjuvants. Adv. Drug Deliv. Rev. 64 (2012), 540–556, 10.1016/j.addr.2011.10.006.
103. [103] Lu, R.H., Kopecková, P., Kopecek, J., Degradation and aggregation of human calcitonin in vitro. Pharm. Res. 16 (1999), 359–367.
104. [104] Maroni, A., Zema, L., Del Curto, M.D., Foppoli, A., Gazzaniga, A., Oral colon delivery of insulin with the aid of functional adjuvants. Adv. Drug Deliv. Rev. 64 (2012), 540–556, 10.1016/j.addr.2011.10.006.
105. [105] Pridgen, E.M., Alexis, F., Farokhzad, O.C., Polymeric nanoparticle technologies for oral drug delivery. Clin. Gastroenterol. Hepatol. 12 (2014), 1605–1610, 10.1016/j.cgh.2014.06.018.
106. [106] LaVan, D.A., McGuire, T., Langer, R., Small-scale systems for in vivo drug delivery. Nat. Biotechnol. 21 (2003), 1184–1191, 10.1038/nbt876.
107. [107] Pinto Reis, C., Neufeld, R.J., Ribeiro, A.J., Veiga, F., Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine 2 (2006), 53–65, 10.1016/j.nano.2006.04.009.
108. [108] Frank, L.A., Contri, R.V., Beck, R.C.R., Pohlmann, A.R., Guterres, S.S., Improving drug biological effects by encapsulation into polymeric nanocapsules. Wiley Interdiscip. Rev. Nanomedicine Nanobiotechnology. 7 (2015), 623–639, 10.1002/wnan.1334.
109. [109] Lin, Y.H., Sonaje, K., Lin, K.M., Juang, J.H., Mi, F.L., Yang, H.W., et al. Multi-ion-crosslinked nanoparticles with pH-responsive characteristics for oral delivery of protein drugs. J. Control. Release 132 (2008), 141–149, 10.1016/j.jconrel.2008.08.020.
110. [110] Sonaje, K., Lin, Y.-H., Juang, J.-H., Wey, S.-P., Chen, C.-T., Sung, H.-W., In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 30 (2009), 2329–2339, 10.1016/j.biomaterials.2008.12.066.
111. [111] Sonaje, K., Lin, K.-J., Wey, S.-P., Lin, C.-K., Yeh, T.-H., Nguyen, H.-N., et al. Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: odelivery using pH-responsive nanoparticles vs. subcutaneous injection. Biomaterials 31 (2010), 6849–6858, 10.1016/j.biomaterials.2010.05.042.
112. [112] Sonaje, K., Chen, Y.-J., Chen, H.-L., Wey, S.-P., Juang, J.-H., Nguyen, H.-N., et al. Enteric-coated capsules filled with freeze-dried chitosan/poly(γ-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials 31 (2010), 3384–3394, 10.1016/j.biomaterials.2010.01.042.
113. [113] Tu, H., Sung, H.-W., Nanoparticles for Protein Drug Delivery, WO 2006073950. 2008, B1.
114. [114] Lin, Y.H., Mi, F.L., Chen, C.T., Chang, W.C., Peng, S.F., Liang, H.F., et al. Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules 8 (2007), 146–152, 10.1021/bm0607776.
115. [115] Su, F.-Y., Lin, K.-J., Sonaje, K., Wey, S.-P., Yen, T.-C., Ho, Y.-C., et al. Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials 33 (2012), 2801–2811, 10.1016/j.biomaterials.2011.12.038.
116. [116] Hosheng Tu, H.-W.S., A Pharmaceutical Composition of Nanoparticles, WO2011133198A1. 2011.
117. [117] Chuang, E.-Y., Nguyen, G.T.H., Su, F.-Y., Lin, K.-J., Chen, C.-T., Mi, F.-L., et al. Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT. Biomaterials 34 (2013), 7994–8001, 10.1016/j.biomaterials.2013.07.021.
118. [118] Nguyen, H.-N., Wey, S.-P., Juang, J.-H., Sonaje, K., Ho, Y.-C., Chuang, E.-Y., et al. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. Biomaterials 32 (2011), 2673–2682, 10.1016/j.biomaterials.2010.12.044.
119. [119] Rao, K.K., Polymerized Solid Lipid Nanoparticles for Oral or Mucosal Delivery of Therapeutic Proteins and Peptides, WO2007113665. 2007.
120. TM oral insulin studies. http://www.transgenebiotek.com/images/inner/news/press_release_120521_tbl_trabioral_insulin_efficacy_studies.pdf, 2012 (accessed December 7, 2015).
121. [121] Transgene Biotek 23rd annual report 2012-2013. http://www.transgenebiotek.com/images/inner/pdf/23rd, 2013 (Annual Reoprt Sept 26 2013.pdf (accessed December 7, 2015)).
122. [122] Pridgen, E.M., Alexis, F., Kuo, T.T., Levy-Nissenbaum, E., Karnik, R., Blumberg, R.S., et al. Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery. Sci. Transl. Med., 5, 2013, 213ra167, 10.1126/scitranslmed.3007049.
123. [123] Bannunah, A.M., Vllasaliu, D., Lord, J., Stolnik, S., Mechanisms of nanoparticle internalization and transport across an intestinal epithelial cell model: effect of size and surface charge. Mol. Pharm. 11 (2014), 4363–4373, 10.1021/mp500439c.
124. [124] Maggio, E.T., Novel Formulations for Non-Invasive Delivery and Stabilization of Peptides. 2013, Drug Dev. Deliv, October.
125. [125] Maggio, E.T., Stabilizing Alkylglycoside Compositions and Methods Thereof, US 7,998,927 B2. 2011.
126. [126] Maggio, E.T., Grasso, P., Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster mice. Regul. Pept. 167 (2011), 233–238, 10.1016/j.regpep.2011.02.009.
127. [127] Lee, D.W., Leinung, M.C., Grasso, P., Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male Swiss Webster mice: a study comparing the pharmacokinetics of oral delivery to intraperitoneal, subcutaneous, intramuscular, and intranasal administration. Regul. Pept. 160 (2010), 129–132, 10.1016/j.regpep.2009.12.008.
128. [128] Leinung, M.C., Grasso, P., [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice. Regul. Pept. 179 (2012), 33–38, 10.1016/j.regpep.2012.08.006.
129. [129] Hay, T., Can “robotic” pills replace injections?. http://www.wsj.com/articles/SB10001424052702304899704579389042422328308, 2014 (accessed December 9, 2015).
130. [130] Interview: Mir Imran, Rani Therapeutics. Drug Deliv., 2015, 32–35 ( http://a.wethrive.com/ext/rani/docs/Rani_HR.pdf (accessed December 7, 2015)).
131. [131] Pre-clinical Data on Insulin and Adalimumab (Humira). 2014, 1–4 ( http://a.wethrive.com/ext/rani/docs/rani_pre-clinical_data_July_2014_1.pdf accessed December 9, 2015).
132. [132] Traverso, G., Schoellhammer, C.M., Schroeder, A., Maa, R., Lauwers, G.Y., Polat, B.E., et al. Microneedles for drug delivery via the gastrointestinal tract. J. Pharm. Sci. 104 (2015), 362–367, 10.1002/jps.24182.
133. [133] Steve Bell, Q.H., Tulin Morco, Therapeutic Calcium Phosphate Particles and Methods of Manufacture and Use, US20010048925 A1. 2001.
134. [134] Li, J., Wang, Y., Han, L., Sun, X., Yu, H., Yu, Y., Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. Clin. Ther. 34 (2012), 2333–2338, 10.1016/j.clinthera.2012.11.004.
135. [135] NOD pharmaceuticals, pipeline: focus on diabetes. http://www.nodpharm.com/products.html, 2015 (accessed December 7, 2015).
136. [136] Vol, A., Gribova, O., Methods and Compositions for Oral Administration of Protein and Peptide Therapeutic Agents, US 8936786 B2. 2015.
137. [137] Walsh, E.G., Adamczyk, B.E., Chalasani, K.B., Maher, S., O'Toole, E.B., Fox, J.S., et al. Oral delivery of macromolecules: rationale underpinning Gastrointestinal Permeation Enhancement Technology (GIPET). Ther. Deliv. 2 (2011), 1595–1610, 10.4155/tde.11.132.
138. [138] Krug, S.M., Amasheh, M., Dittmann, I., Christoffel, I., Fromm, M., Amasheh, S., Sodium caprate as an enhancer of macromolecule permeation across tricellular tight junctions of intestinal cells. Biomaterials 34 (2013), 275–282, 10.1016/j.biomaterials.2012.09.051.
139. [139] Interim results for the six month period ended 30 June 2014. http://www.merrionpharma.com/content/investors/archive/2014/290914.asp, 2014 (accessed December 7, 2015).
140. [140] Kidron, M., Methods and Compositions for Oral Administration of Proteins, WO2007029238. 2009.
141. [141] Eldor, R., Kidron, M., Arbit, E., Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects. Diabetes Obes Metab 12 (2010), 219–223.
142. [142] Eldor, R., Arbit, E., Corcos, A., Kidron, M., Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study. PLoS ONE, 8, 2013, e59524, 10.1371/journal.pone.0059524.
143. [143] Oramed pharmaceuticals reports positive top-line data from U.S. Phase IIa trial with oral insulin in type 1 diabetes. http://www.oramed.com/oramed-pharmaceuticals-reports-positive-top-line-data-from-u-s-phase-iia-trial-with-oral-insulin-in-type-1-diabetes/, 2014 (accessed December 15, 2015).
144. [144] Oramed pharmaceuticals presents data from Phase IIa trial with ORMD-0801 in type 2 diabetes at the 2014 Diabetes Summit. http://www.oramed.com/oramed-pharmaceuticals-presents-data-from-phase-iia-trial-with-ormd-0801-in-type-2-diabetes-at-the-2014-diabetes-summit/, 2014 (accessed December 15, 2015).
145. [145] Oramed enrolls first patient in its Phase IIb oral insulin study. http://www.oramed.com/oramed-enrolls-first-patient-in-its-phase-iib-oral-insulin-study/, 2015 (accessed December 9, 2015).
146. [146] Oramed Pharmaceuticals, pipeline. http://www.oramed.com/pipeline/, 2015 (accessed December 7, 2015).
147. [147] R.R.C. New, Absorption Enhancers, WO2002028436 A1. 2002.
148. [148] Luzio, S.D., The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes, diabetes. Obes. Metab. 12 (2010), 82–87.
149. [149] Advancing oral therapies for diabetes. http://www.diabetology.co.uk/images/Diabetology_Briefing_2014-01-29.pdf, 2014 (accessed December 15, 2015).
150. [150] Bone Medical, Annual Report. 2015 http://www.bone-ltd.com/announcements_files/BNE_AR15.pdf (accessed December 7, 2015).
151. [151] Lau, J.R., Geho, W.B., Orally Bioavailable Lipid Constructs, US 8962015. 2015, B2.
152. [152] Geho, W.B., Geho, H.C., Lau, J.R., Gana, T.J., Hepatic-directed vesicle insulin: a review of formulation development and preclinical evaluation. J. Diabetes Sci. Technol. 3 (2009), 1451–1459.
153. [153] Geho, W.B., Rosenberg, L.N., Schwartz, S.L., Lau, J.R., Gana, T.J., A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral antidiabetic treatment in patients with type 2 diabetes mellitus. J. Diabetes Sci. Technol. 8 (2014), 551–559, 10.1177/1932296814524871.
154. [154] Schwartz, S., Geho, B., Rosenberg, L., Lau, J., A two-week randomized active comparator study of two HDV-insulin routes (sc and oral) and sc human insulin in patients with type 1 diabetes mellitus. http://diasomepharmaceuticals.com/wp-content/uploads/2015/07/two-week-randomized-active-comparator.pdf, 2015 (accessed December 15, 2015).
155. [155] Diasome pharmaceuticals, pipeline. http://diasomepharmaceuticals.com/pipeline/, 2015 (accessed December 7, 2015).
156. [156] Coulter, I., Oral Pharmaceutical Compositions, US20100255087. 2010.
157. [157] Aguirre, T.A.S., Rosa, M., Coulter, I.S., Brayden, D.J., In vitro and in vivo preclinical evaluation of a minisphere emulsion-based formulation (SmPill®) of salmon calcitonin. Eur. J. Pharm. Sci. 79 (2015), 102–111, 10.1016/j.ejps.2015.09.001.
158. [158] Keohane, K., Rosa, M., Coulter, I.S., Griffin, B.T., Enhanced colonic delivery of ciclosporin A self-emulsifying drug delivery system encapsulated in coated minispheres. Drug Dev. Ind. Pharm. 42 (2016), 245–253.
159. [159] Sigmoid Pharma announces CyCol® data presentation at the British and Irish gastroenterology spring meeting. http://www.sigmoidpharma.com/dynamicdata/cycol_data_presentation_0413.asp, 2013 (accessed December 15, 2015).
160. [160] Cho, Y.W., Flynn, M., Oral delivery of insulin. Lancet 2 (2012), 1518–1519.
161. [161] Hazra, P., Adhikary, L., Dave, N., Khedkar, A., Manjunath, H.S., Anantharaman, R., et al. Development of a process to manufacture PEGylated orally bioavailable insulin. Biotechnol. Prog. 26 (2010), 1695–1704, 10.1002/btpr.487.
162. [162] Khedkar, A., Iyer, H., Anand, A., Verma, M., Krishnamurthy, S., Savale, S., et al. A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects, Diabetes. Obes. Metab. 12 (2010), 659–664, 10.1111/j.1463-1326.2010.01213.x.
163. [163] Heinemann, L., Jacques, Y., Oral insulin and buccal insulin: a critical reappraisal. J. Diabetes Sci. Technol. 3 (2009), 568–584, 10.1177/193229680900300323.
164. [164] Biocon Annual Report 2015. http://www.biocon.com/docs/Biocon_Annual_Report_2015.pdf, 2015 (accessed December 15, 2015).
165. [165] Park, K., Kwon, I.C., Park, K., Oral protein delivery: current status and future prospect. React. Funct. Polym. 71 (2011), 280–287, 10.1016/j.reactfunctpolym.2010.10.002.
166. [166] Karsdal, M.A., Byrjalsen, I., Henriksen, K., Riis, B.J., Lau, E.M., Arnold, M., et al. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study. Osteoarthr. Cartil. 18 (2010), 150–159, 10.1016/j.joca.2009.08.004.
167. [167] Karsdal, M.A., Byrjalsen, I., Alexandersen, P., Bihlet, A., Andersen, J.R., Riis, B.J., et al. Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials. Osteoarthr. Cartil. 23 (2015), 532–543, 10.1016/j.joca.2014.12.019.
168. [168] Emisphere Technologies, Inc. reports notification of first interpretable results on phase III study of oral calcitonin in osteoporosis patients. http://ir.emisphere.com/releasedetail.cfm?releaseid=623329, 2011 (accessed December 15, 2015).
169. [169] Oral GLP-1 analogues and oral insulins for type 2 diabetes. http://www.emisphere.com/oral_GLP-1.html, 2015 (accessed December 15, 2015).
170. [170] Kasper, K., Poulsen, R., Novo Nordisk announces positive results for phase 2 trial with oral semaglutide in people with type 2 diabetes. 2015 https://www.novonordisk.com/bin/getPDF.1896081.pdf (accessed December 15, 2015).
171. [171] Castelli, M.C., Wong, D.F., Friedman, K., Riley, M.G.I., Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects. Clin. Ther. 33 (2011), 934–945, 10.1016/j.clinthera.2011.05.088.
172. [172] Novo Nordisk to initiate phase 3a development of oral semaglutide, a once-daily oral GLP-1 analogue. http://www.novonordisk.com/bin/getPDF.1947638.pdf, 2015 (accessed December 15, 2015).
173. [173] Wang, X., Maher, S., Brayden, D.J., Rapid restoration of the colonic epithelium of rats after in situ instillation of the absorption promoter, sodium caprate. Ther. Deliv. 1 (2010), 75–82.
174. [174] Stern, W., Mehta, N., Carl, S., Oral delivery of peptides by Peptelligence technology. Drug Dev. Deliv. 13 (2013), 36–42.
175. [175] Grant, M., Leone-Bay, A., Peptide therapeutics: it's all in the delivery. Ther. Deliv. 3 (2012), 981–996.
176. [176] Tarsa Therapeutics’ NDA for TBRIA(TM), the first oral calcitonin for the treatment of postmenopausal osteoporosis, accepted for filing. http://tarsatherapeutics.com/tarsa-therapeutics-nda-for-tbriatm-the-first-oral-calcitonin-for-the-treatment-of-postmenopausal-osteoporosis-accepted-for-filing/, 2015 (accessed December 15, 2015).
177. [177] Chen, Z., Xu, P., Barbier, J.-R., Willick, G., Ni, F., Solution structure of the osteogenic 1-31 fragment of the human parathyroid hormone. Biochemistry 39 (2000), 12766–12777.
178. [178] Sturmer, A., Mehta, N., Giacchi, J., Cagatay, T., Tavakkol, R., Mitta, S., et al. Pharmacokinetics of oral recombinant human parathyroid hormone [rhPTH(1-31)NH2] in postmenopausal women with osteoporosis. Clin. Pharmacokinet. 52 (2013), 995–1004, 10.1007/s40262-013-0083-4.
179. [179] Henriksen, K., Andersen, J.R., Riis, B.J., Mehta, N., Tavakkol, R., Alexandersen, P., et al. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1–31)NH2] in postmenopausal women with osteoporosis. Bone 53 (2013), 160–166, 10.1016/j.bone.2012.11.045.
180. [180] Aldrich, J.V., McLaughlin, J.P., Opioid peptides: potential for drug development. Drug Discov. Today Technol. 9 (2012), e23–e31, 10.1016/j.ddtec.2011.07.007.
181. [181] Tuvia, S., Pelled, D., Marom, K., Salama, P., Levin-Arama, M., Karmeli, I., et al. A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms. Pharm. Res. 31 (2014), 2010–2021, 10.1007/s11095-014-1303-9.
182. [182] Tuvia, S., Atsmon, J., Teichman, S.L., Katz, S., Salama, P., Pelled, D., et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J. Clin. Endocrinol. Metab. 97 (2012), 2362–2369, 10.1210/jc.2012-1179.
183. [183] Maher, S., Brayden, D.J., Overcoming poor permeability: translating permeation enhancers for oral peptide delivery. Drug Discov. Today Technol. 9 (2012), e113–e119, 10.1016/j.ddtec.2011.11.006.
184. [184] Search orphan drug designations and approvals - octreotide. http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=114598, 2015 (accessed December 15, 2015).
185. [185] Melmed, S., Popovic, V., Bidlingmaier, M., Mercado, M., van der Lely, A.J., Biermasz, N., et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J. Clin. Endocrinol. Metab. 100 (2015), 1699–1708, 10.1210/jc.2014-4113.
186. [186] Chiasma announces FDA acceptance for filing of new drug application for octreotide capsules in acromegaly. http://ir.chiasmapharma.com/phoenix.zhtml?c=254057&p=irol-newsArticle&ID=2079900, 2015 (accessed December 15, 2015).
187. [187] Comiskey, S., Feng, R., Foss, J., Shailubhai, K., Formulations of Guanylate Cyclase c Agonists and Methods of Use, WO 2012037380 A2. 2012.
188. [188] Shailubhai, K., Comiskey, S., Foss, J.A., Feng, R., Barrow, L., Comer, G.M., et al. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Dig. Dis. Sci. 58 (2013), 2580–2586, 10.1007/s10620-013-2684-z.
189. [189] Shailubhai, K., Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis. World J. Gastrointest. Pharmacol. Ther. 6 (2015), 213–222, 10.4292/wjgpt.v6.i4.213.
190. [190] Miner, P.B., Surowitz, R., Fogel, R., Koltun, W., Drossman, D.A., Camilleri, M., et al. Plecanatide, a novel guanylate cyclase-C (GC-C) receptor agonist, is efficacious and safe in patients with chronic idiopathic constipation (CIC): results from a 951 patient, 12 week, multi-center trial. Gastroenterology, 144, 2013, 10.1016/S0016-5085(13)60585-5 (S–163).
191. [191] Miner, P., DeLuca, R., La Portilla, M., Padila, E., Koltun, W., Wiltz, O., et al. Plecanatide, a novel uroguanylin analog: a 12-week, randomized, double-blind, placebo-controlled, dose-ranging trial to evaluate efficacy and safety in patients with irritable bowel syndrome with constipation (IBS-C). Progr. No. 14. ACG 2014 Annu. Sci. Meet. Abstr., Philadelphia, PA, 2014 ( http://www.eventscribe.com/2014/acg/PostersTitles.asp?sort=num&dir=&h=Browse by Number).
192. [192] Synergy pharmaceuticals announces positive results of SP-333 phase 2 trial in patients with opioid-induced constipation. http://www.synergypharma.com/news/press-releases/detail/1734/synergy-pharmaceuticals-announces-positive-results-of, 2014 (accessed December 15, 2015).
193. [193] Dolcanatide. http://www.synergypharma.com/our-pipeline/dolcanatide, 2015 (accessed December 15, 2015).
194. [194] Zijlstra, E., Heinemann, L., Plum-Morschel, L., Oral insulin reloaded: a structured approach. J. Diabetes Science Technol., 8, 2014, 558-465, 10.1177/1932296814529988.
195. [195] Moroz, E., Matoori, S., Leroux, J.-C., Oral delivery of macromolecular drugs: where we are after almost 100 years of attempts. Adv. Drug Deliv. Rev. 101 (2016), 108–121.